section name header

Indications ⬇

REMS


Unlabeled Use:

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Derm: acute generalized exanthematous pustulosis, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), ERYTHEMA MULTIFORME, moniliasis (children only), pruritus, rash, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS (TEN)

GI: diarrhea, nausea, vomiting, CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD), constipation, glossitis (↑ in children), thrush (↑ in children)

Hemat: thrombocytopenia (↑ in renal impairment)

Local: inflammation at injection site, phlebitis

Neuro: dizziness, headache, paresthesias, SEIZURES

Resp: APNEA

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)

Interactions ⬆ ⬇

Drug-drug:

Availability ⬆ ⬇

(Generic available)

Route/Dosage ⬆ ⬇

Complicated Skin/Skin Structure Infections

Renal Impairment

Intra-abdominal Infections

Renal Impairment

Bacterial Meningitis

US Brand Names ⬆ ⬇

Merrem

Action ⬆ ⬇

  • Binds to bacterial cell wall, resulting in cell death.
  • Meropenem resists the actions of many enzymes that degrade most other penicillins and penicillin-like anti-infectives.
Therapeutic effects:
  • Bactericidal action against susceptible bacteria.

Spectrum:

Classifications ⬆ ⬇

Therapeutic Classification: anti-infectives

Pharmacologic Classification: carbapenems

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results in complete bioavailability.

Distribution: Widely distributed to tissues; enters CSF when meninges are inflamed.

Metabolism/Excretion: Primarily metabolized by the liver; 50–75% excreted unchanged by the kidneys.

Half-Life: Premature neonates: 3 hr; Term neonates: 2 hr; Infants (3 mo–2 yr) 1.4 hr; Children >2 yr and Adults: 1 hr (↑ in renal impairment).

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTEONSETPEAKDURATION
IVrapidend of infusion8 hr

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆ ⬇

mer-oh-PEN-nem

Code ⬆

NDC Code